Deletion of Crry, the Murine Ortholog of the Sporadic Alzheimer's Disease Risk Gene CR1, Impacts Tau Phosphorylation and Brain CFH

Overview

Journal Neurosci Lett

Specialty Neurology

Date 2012 Nov 17

PMID 23153828

Citations 12

Authors

R Killick

T R Hughes

B P Morgan

S Lovestone

Affiliations

Soon will be listed here.

Abstract

Large-scale genome-wide SNP association studies have identified an association between variants of CR1, the gene encoding complement component receptor 1, and the sporadic form of Alzheimer's disease. The role of CR1 and the complement system in Alzheimer's disease remains far from clear. In rodents the closest ortholog of CR1 is the Crry gene (Cr1-related protein Y). To begin to explore its role in Alzheimer's disease we examined hippocampal lysates from Crry(-/-) mice and age matched controls by immunoblotting. We measured complement factor H, a component of the complement system and biomarker for Alzheimer's disease progression, and tau phosphorylation at the serine 235 site, hyperphosphorylated forms of tau being a defining neuropathological hallmark of the disease. We found that levels of CFH and of tau phosphorylation at serine 235 were strongly and significantly reduced in Crry(-/-) samples. These observations provide a starting point for further attempts to determine the role of CR1 in the neuropathological process driving Alzheimer's disease.

Citing Articles

A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer's disease: A preliminary study of tau PET and cognitive outcomes.

Wang X, Broce I, Qiu Y, Deters K, Fan C, Dale A Alzheimers Dement. 2023; 19(7):3078-3086.

PMID: 36701211 PMC: 10368787. DOI: 10.1002/alz.12952.

Identification of Sex-Specific Genetic Variants Associated With Tau PET.

Wang X, Broce I, Deters K, Fan C, Banks S Neurol Genet. 2022; 8(6):e200043.

PMID: 36530928 PMC: 9756308. DOI: 10.1212/NXG.0000000000200043.

Association of the top 20 Alzheimer's disease risk genes with [F]flortaucipir PET.

Stage E, Risacher S, Lane K, Gao S, Nho K, Saykin A Alzheimers Dement (Amst). 2022; 14(1):e12308.

PMID: 35592828 PMC: 9092485. DOI: 10.1002/dad2.12308.

Crry silencing alleviates Alzheimer's disease injury by regulating neuroinflammatory cytokines and the complement system.

Zhu X, Liu L, Dai W, Ma T Neural Regen Res. 2022; 17(8):1841-1849.

PMID: 35017447 PMC: 8820699. DOI: 10.4103/1673-5374.332160.

A novel mouse model expressing human forms for complement receptors CR1 and CR2.

Jackson H, Foley K, ORourke R, Stearns T, Fathalla D, Morgan B BMC Genet. 2020; 21(1):101.

PMID: 32907542 PMC: 7487969. DOI: 10.1186/s12863-020-00893-9.

References

Morgan K . The three new pathways leading to Alzheimer's disease. Neuropathol Appl Neurobiol. 2011; 37(4):353-7. DOI: 10.1111/j.1365-2990.2011.01181.x. View

Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y . Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry. 2010; 67(7):739-48. PMC: 3111021. DOI: 10.1001/archgenpsychiatry.2010.78. View

Xu C, Mao D, Holers V, Palanca B, Cheng A, Molina H . A critical role for murine complement regulator crry in fetomaternal tolerance. Science. 2000; 287(5452):498-501. DOI: 10.1126/science.287.5452.498. View

Goedert M, Jakes R, Crowther R, Cohen P, Vanmechelen E, Vandermeeren M . Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem J. 1994; 301 ( Pt 3):871-7. PMC: 1137067. DOI: 10.1042/bj3010871. View

Alonso A, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K . Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem. 2004; 279(33):34873-81. DOI: 10.1074/jbc.M405131200. View

Strohmeyer R, Ramirez M, Cole G, Mueller K, Rogers J . Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain. J Neuroimmunol. 2002; 131(1-2):135-46. DOI: 10.1016/s0165-5728(02)00272-2. View

Fingeroth J, Benedict M, Levy D, Strominger J . Identification of murine complement receptor type 2. Proc Natl Acad Sci U S A. 1989; 86(1):242-6. PMC: 286440. DOI: 10.1073/pnas.86.1.242. View

Crehan H, Holton P, Wray S, Pocock J, Guerreiro R, Hardy J . Complement receptor 1 (CR1) and Alzheimer's disease. Immunobiology. 2011; 217(2):244-50. DOI: 10.1016/j.imbio.2011.07.017. View

Thambisetty M, Hye A, Foy C, Daly E, Glover A, Cooper A . Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol. 2009; 255(11):1712-20. DOI: 10.1007/s00415-008-0006-8. View

10.

Killick R, Scales G, Leroy K, Causevic M, Hooper C, Irvine E . Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun. 2009; 386(1):257-62. PMC: 2726921. DOI: 10.1016/j.bbrc.2009.06.032. View

11.

Lambert J, Heath S, Even G, Campion D, Sleegers K, Hiltunen M . Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet. 2009; 41(10):1094-9. DOI: 10.1038/ng.439. View

12.

Pramoonjago P, Takeda J, Kim Y, Inoue K, Kinoshita T . Ligand specificities of mouse complement receptor types 1 (CR1) and 2 (CR2) purified from spleen cells. Int Immunol. 1993; 5(4):337-43. DOI: 10.1093/intimm/5.4.337. View

13.

Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K . Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys. 1998; 357(2):299-309. DOI: 10.1006/abbi.1998.0813. View

14.

Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers H . Proteome-based plasma biomarkers for Alzheimer's disease. Brain. 2006; 129(Pt 11):3042-50. DOI: 10.1093/brain/awl279. View

15.

Velazquez P, Cribbs D, Poulos T, Tenner A . Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nat Med. 1997; 3(1):77-9. DOI: 10.1038/nm0197-77. View

16.

Cho J, Johnson G . Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem. 2003; 88(2):349-58. DOI: 10.1111/j.1471-4159.2004.02155.x. View

17.

Kinoshita T, Takeda J, Hong K, Kozono H, Sakai H, Inoue K . Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. J Immunol. 1988; 140(9):3066-72. View

18.

Brunden K, Trojanowski J, Lee V . Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov. 2009; 8(10):783-93. PMC: 2787232. DOI: 10.1038/nrd2959. View

19.

Ruseva M, Hughes T, Donev R, Sivasankar B, Pickering M, Wu X . Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. Mol Immunol. 2008; 46(5):803-11. DOI: 10.1016/j.molimm.2008.09.003. View

20.

Biernat J, Gustke N, Drewes G, Mandelkow E, Mandelkow E . Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron. 1993; 11(1):153-63. DOI: 10.1016/0896-6273(93)90279-z. View